healthlinx ltd
(HTX:Australian Stock Exchange - SEATS)
healthlinx ltd (HTX) Snapshot
|
Open
A$0.0010
|
Previous Close
A$0.0010
|
|
|
Day High
A$0.0010
|
Day Low
A$0.0010
|
|
|
52 Week High
05/18/12 - A$0.0070
|
52 Week Low
10/3/12 - A$0.0010
|
|
|
Market Cap
969.1K
|
Average Volume 10 Days
0.0
|
|
|
EPS TTM
A$-0.0089
|
Shares Outstanding
969.1M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
healthlinx ltd (HTX) Related Businessweek News
No Related Businessweek News Foundhealthlinx ltd (HTX) Details
HealthLinx Limited, a biomarker and diagnostic company, focuses on the development of novel blood based diagnostics for targeted diseases that have un-met market need. It develops novel, non-invasive, serum-based, diagnostic products. The company offers OvPlex, a diagnostic test for the early detection of ovarian cancer in symptomatic women. It also develops AGR2, a tumour-related protein that has been shown to be upregulated in various human cancers, including carcinoma of the ovary, prostate, and breast. HealthLinx Limited markets its OvPlex in Australia, Singapore, the United Kingdom, and the Republic of Ireland. It has a licensing agreement with Millipore to use AGR2 as a research tool; and licensing/distribution agreements with Medison Pharma to distribute OvPlex in Israel and with SCL to distribute OvPlex in South Korea. The company is based in Richmond, Australia.
healthlinx ltd (HTX) Top Compensated Officers
healthlinx ltd (HTX) Key Developments
HealthLinx Limited announced the resignation of director, Mr. Nick Gatsios effective immediately. The Board announced the appointment of Mr. Trent Telford and Mr. Richard Revelins as directors effective immediately. Mr. Telford is a resident of Sydney and is a founder and director of Australian based technology companies, including Cocoon Data Limited. Mr. Revelins is a resident of California and has over 25 years experience in raising capital for ASX listed companies. He is an executive director and principal of Peregrine Corporate Limited.
HealthLinx Limited reported consolidated earnings results for the six months ended December 31, 2012. For the period, the company reported revenue of AUD 22,067 against AUD 177,343 for the same period last year. Total revenue and other income was AUD 86,774 against AUD 180,343 for the same period last year. Loss before income tax was AUD 3,177,949 against AUD 1,162,406 for the same period last year. Net loss was AUD 2,775,578 or 0.004 cents per basic and diluted share against AUD 825,997 or 0.007 cents per basic and diluted share for the same period last year. Net cash used in operating activities was AUD 554,094 against AUD 1,189,189 for the same period last year. Payments for intangibles were AUD 56,988 against AUD 112,827 for the same period last year.
HealthLinx Limited announced that they will report first half, 2013 results on Feb 28, 2013
| Recently Viewed | |||
| HTX:AU | A$0.00 AUD | 0.00 | |
| Company | Last | Change | |
| No competitor information is available for HTX. | |||
| View Industry Companies | |||
Industry Analysis
HTX
Industry Average
| Valuation | HTX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 6.5x |
|
| Price/Book | 4.1x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 7.2x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- New York, NY | New York UniversityPosted: Apr 19
Sponsored Financial Commentaries
Sponsored Links
To contact HEALTHLINX LTD, please visit www.healthlinx.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








